Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 335.00
Bid: 333.50
Ask: 335.50
Change: 6.50 (1.98%)
Spread: 2.00 (0.60%)
Open: 323.00
High: 335.00
Low: 323.00
Prev. Close: 328.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: DFS Furniture gains share of weak market

Thu, 21st Sep 2023 09:40

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

----------

SMALL-CAP - WINNERS

----------

DFS Furniture PLC, up 4.9% 112.45p, 12-month range 101p-170p. The sofa retailer continues to win UK market share in a "very tough market" during its financial year, which ended on June 25, and outlines a path to improving margins. DFS says revenue from continuing operations fell 5.2% year-on-year to GBP1.09 billion from GBP1.15 billion, as pretax profit slumps 49% to GBP29.7 million from GBP58.5 million. Underlying profit before tax and brand amortisation is GBP30.6 million, which is in line with its interim guidance. DFS expects underlying profit before tax and brand amortisation to improve by a low single-digit percentage in financial 2024 to a GBP30 million to GBP35 million range. This assumes market volumes fall 5%, DFS notes. "We are confident the market will recover; however we can't predict how quickly that will happen. We have a clear route to a 5% [profit before tax] margin without market recovery, supported by further margin improvement, new cost efficiencies, and continued growth in Home," DFS says.

----------

Oxford BioMedica PLC, up 5.4% at 283.50 pence, 12-month range 236.50-575.00p. The cell and gene therapy company adds to Wednesday's gains after it announced exclusive talks with Institut Meriueux SA about buying ABL Europe, a pure-play European contract development and manufacturing organization. As part of the deal, Institut Merieux would become one of its major shareholders. The stock is down 16% over the past month however.

----------

SMALL-CAP - LOSERS

----------

James Fisher & Sons PLC, down 2.5% at 345.14p, 12-month range 241p-427.5p. The marine services swings to a pretax loss in the first half of 2023 of GBP4.4 million from a profit of GBP5.2 million a year before. This comes despite revenue rising 17% GBP252.0 million from GBP215.0 million. The loss is due to GBP9.3 million in refinancing legal and advisory costs, as well as higher interest rates, offsetting a positive operating performance, James Fisher explains. "All three divisions delivered revenue and profit growth against the first half of 2022, with a particularly strong increase seen in the Energy division," says CEO Jean Vernet. Trading in July and August is in line with its expectations, and James Fisher leaves its full-year expectations unchanged.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
6 May 2020 12:52

Oxford Biomedica swings to loss as licensing revenue falls

(Sharecast News) - Gene and cell therapy company Oxford Biomedica reported an improvement in bioprocessing and commercial development revenues to ?47.3m in its preliminary results on Wednesday, from ?40.5m.

Read more
29 Apr 2020 16:13

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
28 Apr 2020 11:13

Liberum hikes target price on Oxford Biomedica

(Sharecast News) - Analysts at Liberum hiked their target price on gene and cell therapy company Oxford BioMedica from £8.60 per share to £10.90 on Tuesday, citing demand at its new OxBox manufacturing facility.

Read more
8 Apr 2020 16:13

Oxford Biomedica joins Covid-19 vaccine consortium

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has joined a consortium led by the Jenner Institute at Oxford University, it announced on Wednesday, to rapidly develop, scale-up and manufacture a potential vaccine candidate for Covid-19, called 'ChAdOx1 nCov-19'.

Read more
8 Apr 2020 14:46

UK TRADING UPDATE SUMMARY: Novacyt Gets WHO Covid-19 Test Kit Okay

UK TRADING UPDATE SUMMARY: Novacyt Gets WHO Covid-19 Test Kit Okay

Read more
20 Mar 2020 15:57

DIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares

DIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares

Read more
19 Mar 2020 10:59

Oxford Biomedica Expects 2019 Loss As Chair Steps Down, Signs New Deal

Oxford Biomedica Expects 2019 Loss As Chair Steps Down, Signs New Deal

Read more
4 Feb 2020 12:10

Oxford Biomedica Sells USD8.4 Million In Orchard Therapeutics Shares

Oxford Biomedica Sells USD8.4 Million In Orchard Therapeutics Shares

Read more
19 Dec 2019 16:27

Oxford Biomedica Extends Agreement With Novartis By Five Years

Oxford Biomedica Extends Agreement With Novartis By Five Years

Read more
30 Sep 2019 09:55

BROKER RATINGS SUMMARY: Barclays Cuts Whitbread And Raises SSE

BROKER RATINGS SUMMARY: Barclays Cuts Whitbread And Raises SSE

Read more
28 May 2019 13:18

Novo Holdings pours ?53.5m into Oxford Biomedica

(Sharecast News) - Gene and cell therapy company Oxford Biomedica announced on Tuesday that Novo Holdings has agreed to invest up to £53.5m in the group, in return for new ordinary shares representing up to 10.1% of the outstanding shares after the capital increase.

Read more
15 Mar 2019 12:46

Friday broker round-up

(Sharecast News) - Bakkavor Group: Berenberg downgrades to sell with a target price of 105p.

Read more
14 Mar 2019 14:16

Oxford Biomedica swings to positive earnings in 2018

(Sharecast News) - Gene and cell therapy group Oxford Biomedica reported a 72% increase in gross income in its preliminary results for the year ended 31 December on Thursday, to £67.9m.

Read more
12 Mar 2019 10:10

Oxford Biomedica enters research collaboration with Microsoft

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has entered into a research and development collaboration with Microsoft Research, it announced on Tuesday, to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning.

Read more
23 Nov 2018 10:59

Oxford BioMedica forms new digital framework initiative

(Sharecast News) - Gene and cell therapy group Oxford BioMedica announced the formation of a new digital framework initiative on Friday, which it said would streamline the production of next-generation medicines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.